Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-29. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== Biography == Cantley grew up in West Virginia, remaining there at Wesleyan College where he graduated summa cum laude in chemistry in 1971. Cantley obtained his PhD at Cornell University in Ithaca, New York, where he worked with Gordon Hammes on enzyme kinetics, using FRET to study enzyme conformational changes. In 1975 he moved to Harvard University for a postdoctoral fellowship under Guido Guidotti, where he discovered that an impurity in commercial preparations of ATP, vanadate, acts as a transition state analog for phosphate hydrolysis. In 1978 Cantley became assistant professor of Biochemistry and Molecular Biology at Harvard, being promoted to associate professor in 1981. In 1985, he became a full professor in physiology at Tufts University School of Medicine. In 1985 Cantley and colleagues Malcolm Whitman, David Kaplan, Tom Roberts, and Brian Schaffhausen made the seminal discovery of the existence of phosphoinositide-3-kinase (PI3K). In 1992, Cantley moved to Harvard Medical School as a Professor of Cell Biology and the Director of the Division of Signal Transduction at the former Beth Israel Hospital (now Beth Israel Deaconess Medical Center). In 2003, Cantley became a founding member of the newly formed Department of Systems Biology at Harvard Medical School. In 2007, Cantley also became the Director of Cancer Research at the Beth Israel Deaconess Medical Center. He joined the faculty of Weill Cornell Medicine and NewYork–Presbyterian Hospital in 2012. Dr. Cantley was elected the Chairman of the Board of the Hope Funds for Cancer Research in 2016.
In the large intestine the passage of the digesting food in the colon is a lot slower, taking from 30 to 40 hours until it is removed by defecation. The colon mainly serves as a site for the fermentation of digestible matter by the gut flora. The time taken varies considerably between individuals. The remaining semi-solid waste is termed feces and is removed by the coordinated contractions of the intestinal walls, termed peristalsis, which propels the excreta forward to reach the rectum and exit through the anus via defecation. The wall has an outer layer of longitudinal muscles, the taeniae coli, and an inner layer of circular muscles. The circular muscle keeps the material moving forward and also prevents any back flow of waste. Also of help in the action of peristalsis is the basal electrical rhythm that determines the frequency of contractions. The taeniae coli can be seen and are responsible for the bulges (haustra) present in the colon. Most parts of the GI tract are covered with serous membranes and have a mesentery. Other more muscular parts are lined with adventitia.
== Military career == Wilson served with the Rhodesian African Rifles (RAR) before passing selection for the Rhodesian Special Air Service (SAS) in July 1975. He commanded B Squadron from January 1976–February 1978 and was promoted to become second-in-command of the regiment from March 1978–May 1980. He took command in 1980. Wilson's first decoration for valour was the BCR which was awarded on 07 Oct 1977 while he was still a Captain. His second, the SCR, was awarded on 13 April 1979 with Major Wilson in the 2IC post. Following Rhodesia's reconstitution and recognised independence as Zimbabwe in 1980, Wilson was awarded the Grand Cross of Valour on 30 June 1980 while a Major and second-in-command. He was the second and final person to be awarded the honour after Chris Schulenburg, who received the award while serving with the Selous Scouts. Wilson was awarded Wings on Chest (WOC) on 18 April 1979. During Rhodesia's transition to Zimbabwe, Wilson obtained the rank of major and retired after serving as Officer Commanding SAS from April 1980 to the unit's disbandment in December that year. He delivered the final regimental address at Kabrit Barracks on 13 December 1980, before the final lowering of the colours. An account of the role of the SAS in the Rhodesian Bush War was authored by Wilson and Greg Mills, entitled Who Dares Loses: Assessing Rhodesia's Counter-Insurgency Experience. Wilson was appointed as the President of the C-Squadron Rhodesian Special Air Service Association following the death of General Peter Walls.
Sources: en.wikipedia.org
=== Diversification and decline === The ensuing financial crisis prompted a major strategic transition. In 1970, HVEC's losses represented 31 percent of total stockholder investment. The company laid off 100 employees and suspended many research programs, citing insufficient federal funding for basic physics research. That year also marked a leadership transition: Pascal Levesque, head of the profitable HVEC subsidiary Electronized Chemicals Corporation, became president and chief executive, while departing president Denis Robinson assumed the chairmanship held by Trump. Under new management, HVEC diversified into industrial applications of its accelerator technologies. By 1972, the company had reorganized as a miniconglomerate with more than ten subsidiaries manufacturing plastics, power equipment, and radiation processing systems—products enabled by particle accelerators rather than particle accelerators themselves. The diversification strategy yielded several commercially successful products. Electronized Chemicals Corporation's heat-shrink tubing, made by electron-beam crosslinking of polyethylene, became ubiquitous in electrical wiring. The technology enabled modern wire harnesses in automobiles and aircraft, where compact, reliable insulation was essential. Ion Physics Corporation introduced radiation-based ion implantation, enabling precise control of transistor characteristics in integrated circuits. HVEC closed Ion Physics in 1971, but became standard practice throughout the global semiconductor industry by the late 1970s.
Other countries to do so are Canada, Georgia, Germany, Luxembourg, Malta, South Africa, and Thailand. In the U.S., the recreational use of cannabis is legalized in 24 states, 3 territories, and the District of Columbia, though the drug remains federally illegal. In Australia, it is legalized only in the Australian Capital Territory.
Some followers of Islam, or Muslims, chose to be vegetarian for health, ethical, or personal reasons. However, the choice to become vegetarian for non-medical reasons can sometimes be controversial due to conflicting fatwas and differing interpretations of the Quran. Though some more traditional Muslims may keep quiet about their vegetarian diet, the number of vegetarian Muslims is increasing. Sri Lankan Sufi master Bawa Muhaiyaddeen, who established The Bawa Muhaiyaddeen Fellowship of North America in Philadelphia. The former Indian president Dr. A. P. J. Abdul Kalam was also famously a vegetarian. In January 1996, The International Vegetarian Union announced the formation of the Muslim Vegetarian/Vegan Society. Many non-vegetarian Muslims will select vegetarian (or seafood) options when dining in non-halal restaurants. However, this is a matter of not having the right kind of meat rather than preferring not to eat meat on the whole.
=== Legal history === In 1997, three men from the Chicago area sued Hooters after being denied employment at an Orland Park, Illinois, restaurant. Each of them was awarded $19,100. Four men who filed a similar lawsuit in Maryland received $10,350 each. The settlement allows Hooters to continue gender-restricted hiring in its wait staff; the chain agreed to create other support jobs, like bartenders and hosts, that must be filled without regard to gender. In 2000, a federal jury ordered Hooters to pay $275,000 to former waitress Sara Steinhoff, who claimed in her lawsuit that she was the target of unwanted sexual advances, demeaning behavior and recrimination from managers while she worked at the Hooters in Newport, Kentucky, between October 1996 and October 1997. In 2001, a jury determined Hooters of Augusta Inc. willfully violated the Telephone Consumer Protection Act by sending unsolicited advertising faxes. The class-action lawsuit, brought in June 1995 by Sam Nicholson, included 1,320 others who said they received the advertising faxes from Hooters. Atlanta-based Hooters of America Inc., the local restaurant's parent company, paid out $11 million. The jury determined that six faxes were sent to each plaintiff. With a $500 fine for each, that amounts to a $3,000 award per plaintiff. Also in 2001, Jodee Berry, a waitress at a Hooters in Panama City Beach, Florida, won a beer sales contest, for which the promised prize was a new Toyota automobile. However, the manager awarded her a "toy Yoda" instead, claiming the contest was an April Fool's Day joke.
Sources: en.wikipedia.org
The pylorus, the lowest section of the stomach which attaches to the duodenum via the pyloric canal, contains countless glands which secrete digestive enzymes including gastrin. After an hour or two, a thick semi-liquid called chyme is produced. When the pyloric sphincter, or valve opens, chyme enters the duodenum where it mixes further with digestive enzymes from the pancreas, and then passes through the small intestine, where digestion continues. The parietal cells in the fundus of the stomach, produce a glycoprotein called intrinsic factor which is essential for the absorption of vitamin B12. Vitamin B12 (cobalamin), is carried to, and through the stomach, bound to a glycoprotein secreted by the salivary glands – transcobalamin I also called haptocorrin, which protects the acid-sensitive vitamin from the acidic stomach contents. Once in the more neutral duodenum, pancreatic enzymes break down the protective glycoprotein. The freed vitamin B12 then binds to intrinsic factor which is then absorbed by the enterocytes in the ileum. The stomach is a distensible organ and can normally expand to hold about one litre of food. This expansion is enabled by a series of gastric folds in the inner walls of the stomach. The stomach of a newborn baby will only be able to expand to retain about 30 ml.
Returning American strike pilots generally assessed these carriers as more crippled than they actually were, mistaking for devastating direct hits what Japanese post-war records revealed to have actually been huge geysers caused by near misses. The battleship Haruna was also hit by two bombs, including one directly on a main battery turret. Damage was contained, and she was able to keep station because her captain promptly called to flood the turret's magazine to avoid the possibility of an explosion. Twenty American aircraft in the strike were destroyed by Japanese fighters and anti-aircraft fire that made up for a relative lack of accuracy with high volume of fire. After the protracted strike, it became clear that most of the aircraft returning to their carriers were running dangerously low on fuel, and to worsen matters, night had fallen. At 20:45, the first returning U.S. aircraft reached TF 58. Knowing his aviators would have difficulty finding their carriers, Admiral Joseph J. Clark of Hornet decided to illuminate his carrier, shining searchlights directly up into the night, despite the risk of attack from Japanese submarines and night-flying aircraft. Mitscher backed up the decision, and soon every ship in Task Force 58 was lit up, in spite of the risks involved. Picket destroyers fired starshells to help the aircraft find the task groups. Planes were given clearance to land on any available flight deck (not just their home carriers, as usual), and many did land on other carriers. Despite this, 80 of the returning aircraft were lost.
== Thermochemical terminology == Although not substances, the thermochemical concepts entropy and enthalpy were assigned Chinese characters based on similar considerations. The 'fire' radical, 火, is used as the semantic category. The character for entropy, 熵 (pinyin: shāng), is derived from 商 (pinyin: shāng), which means 'quotient' in this context. This recognizes the Clausius equation for the differential change in entropy as the differential heat absorbed divided by the temperature: dS = dQ/T. The character for enthalpy, 焓 (pinyin: hán), is derived from 含 (pinyin: hán), which means 'to contain.' This character phonetically approximates the first syllable of 'enthalpy', and recognizes the definition of enthalpy as heat content.
==== Bacterial ==== Studies have shown that bacterial infections of the human urinary tract, vagina (i.e., bacterial vaginosis), gums (i.e., periodontitis), and abscesses in various tissues are associated with high concentrations of SCFAs, especially acetic acid, at the infection sites or, in urinary tract infections, the urine. These SCFAs may be made and released by the bacteria and/or host cells in the infected areas. Several studies have suggested that SCFAs act through FFAR2 to suppress these infections. 1) Compared to control mice, Ffar2 gene knockout mice had more severe infections in models of Citrobacter rodentium, Klebsiella pneumoniae, Clostridioides difficile, and Streptococcus pneumoniae bacterial infections. 2) Injection of acetic acid into the peritoneum 1/2 hour before or 6 hours after injection of Staphylococcus aureus bacteria into the bloodstream of mice reduced signs of severe disease, the amount of body weight lost, and the numbers of bacteria recovered from the liver, spleen, and kidneys; these reductions did not occur in Fffar2 gene knockdown mice. And, 3) higher circulating blood cell levels of FFAR2 messenger RNA were associated with higher survival rates in patients with sepsis, i.e., disseminated bacterial infections, compared to patients with lower levels of blood cell FFAR2 messenger RNA. These studies suggest that FFAR2 reduces the severity of the cited bacterial infections in humans and mice and recommend further studies on the roles of FFAR2 in these and other bacterial infections.
The 23 s group is attributed mainly to 137I (half-life 24.5 s), which beta decays to excited states of 137Xe that promptly emit a neutron to form stable 136Xe. In both cases the number of neutrons in the emitter exceeds a magic number (50 and 82, respectively) by exactly one neutron, so the last neutron is weakly bound and easily emitted; the other, shorter-lived groups are produced in analogous chains. Delayed Neutron Data for Thermal Fission of U-233, U-235 and Pu-239
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.